Resources
AI Helps Identify Patients Likely To Respond To Treatment During Ophthalmology Clinical Trials
Transcript Hello, my name is George Magrath and I’m the CEO at Lexitas Pharma Services. I’m also an ophthalmologist. And I’d like to talk to you today about the way we’re using machine learning and artificial intelligence in clinical trial work that we do in...
How Diversity, Equity and Inclusion In Clinical Trials Leads To Better Health Outcomes
Almost 20% of new therapeutics have demonstrated differences in exposure and/or response across racial and ethnic groups, according to a study by the American Society for Clinical Pharmacology and Therapeutics.[1] In some cases, this even leads to different...
Lexitas 2023 – Our Vision For The Coming Year
An interview with Lexitas Chief Executive Officer George Magrath, M.D. 2022 was a big year for Lexitas. The company grew substantially since being acquired by a QHP Capital. What are your priorities for Lexitas in 2023 and how will that impact customers? The QHP...
Finding Quality Clinical Research Sites
May 8, 2018 - No sponsor ever intentionally selects a site that will do poorly. No site ever commits to doing a protocol intending at the outset to do a bad job or be non-productive. But everyone knows the substantial costs in terms of time, money, and missed...
Operationalizing a Protocol
March 12, 2018 – You know what you want your study to look like. You have probably done your homework and know what your competitors have tried, what the regulators are expecting/requiring, and you’ve confirmed that you are aligned with current medical practice and...
The Hidden Value of Onsite Monitoring
October 18, 2017 – Ellie Einolhayat, RN, a Lexitas monitor (clinical research associate) provides insight on the role onsite monitors have in identifying issues with protocol design and other challenges that come with successfully executing a clinical trial. To learn...
Subscribe to receive updates
Subscribe to our newsletter to stay up-to-date with Lexitas.